Action PepGen - PEPG

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

1,37

Prix Achat

1,37

Prix Vente

1,65

Volume échangé

0,00 Fourchette du Jour 0,00

1,16 Plage de 52 semaines 19,298

Cap du marché

44,656M

Clôture Veille

1,37

Ouverture

Dernière Transaction

1.65

Dernière heure de transaction

11:21:37

Volume financier

VWAP

Volume moyen (3 m)

337 923

Actions en circulation

32 595 737

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,57

Bénéfice par action (BPA)

-2,41

Chiffre d'affairess

Bénéfice net

-78,63M

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

pepgen.com

Siège social

Wilmington, Delaware, USA

Fondé

PepGen Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker PEPG. Le dernier cours de clôture d'PepGen était de US$1,37. Au cours de la dernière année, les actions de PepGen ont été négociées dans une fourchette de prix de US$ 1,16 à US$ 19,298.

PepGen compte actuellement 32 595 737 actions en circulation. La capitalisation boursière d'PepGen est de US$44,66 million. PepGen a un ratio cours/bénéfice (ratio PE) de -0.57.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable...

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- PepGen Inc. (Nasdaq: PEPG), a...

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.03	2.23880597015	1.34	1.81	1.24	320975	1.42640803	CS
4	-0.53	-27.8947368421	1.9	2.03	1.16	492943	1.35125113	CS
12	-3.63	-72.6	5	6.85	1.16	337923	2.60393304	CS
26	-8.32	-85.8617131063	9.69	10.14	1.16	206473	3.88906783	CS
52	-12.51	-90.1296829971	13.88	19.298	1.16	159735	7.28980701	CS
156	-14.23	-91.2179487179	15.6	20	1.16	124263	9.25187578	CS
260	-14.23	-91.2179487179	15.6	20	1.16	124263	9.25187578	CS

PEPG - Frequently Asked Questions (FAQ)

What is the current PepGen share price?

The current share price of PepGen is US$ 1,37

How many PepGen shares are in issue?

PepGen has 32 595 737 shares in issue

What is the market cap of PepGen?

The market capitalisation of PepGen is USD 44,66M

What is the 1 year trading range for PepGen share price?

PepGen has traded in the range of US$ 1,16 to US$ 19,298 during the past year

What is the PE ratio of PepGen?

The price to earnings ratio of PepGen is -0,57

What is the reporting currency for PepGen?

PepGen reports financial results in USD

What is the latest annual profit for PepGen?

The latest annual profit of PepGen is USD -78,63M

What is the registered address of PepGen?

The registered address for PepGen is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the PepGen website address?

The website address for PepGen is pepgen.com

Which industry sector does PepGen operate in?

PepGen operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
VRMVroom Inc	US$ 24,50 (390,00%)	102
STECSantech Holdings Limited	US$ 2,79 (329,03%)	42,97M
RETOReTo Eco Solutions Inc	US$ 1,22 (200,57%)	20,13M
LINKInterlink Electronics Inc	US$ 13,00 (84,40%)	67
ORISOriental Rise Holdings Ltd	US$ 2,06 (83,93%)	15,19M
PHVSPharvaris NV	US$ 10,01 (-39,30%)	13
EBMTEagle Bancorp Montana Inc	US$ 12,01 (-33,35%)	22
HBNCHorizon Bancorp Inc	US$ 12,30 (-26,65%)	10
WDCWestern Digital Corporation	US$ 52,93 (-22,96%)	6,07k
JUNEJunee Ltd	US$ 3,20 (-22,52%)	3
STECSantech Holdings Limited	US$ 2,79 (329,03%)	42,97M
CNEYCN Energy Group Inc	US$ 0,3673 (50,16%)	35,78M
RETOReTo Eco Solutions Inc	US$ 1,22 (200,57%)	20,13M
ORISOriental Rise Holdings Ltd	US$ 2,06 (83,93%)	15,19M
ADTXAditxt Inc	US$ 0,0827 (-9,62%)	12,19M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PepGen Inc (PEPG)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de PepGen Inc

PEPG Dernières nouvelles

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PEPG - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PepGen Inc (PEPG) Cours

PepGen Inc (PEPG)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de PepGen Inc

PEPG Dernières nouvelles

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Form 8-K - Current report

PepGen Announces CONNECT Program Updates

Form 8-K - Current report

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PEPG - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités